Dihydroartemisinin attenuates pulmonary inflammation and fibrosis in rats by suppressing JAK2/STAT3 signalingResearch Paper Published on 2022-02-152022-10-28 Journal: Aging (Albany NY) [Category] COVID-19, [키워드] activated Activation alveolar inflammation analyzed attenuate cause caused CCL3 change chemokine collagen Coronavirus disease 2019 COVID-19 dihydroartemisinin effective expression fibrosis growth hydroxyproline IL-6 Inflammatory response inhibit inhibited inhibiting inhibitory effect JAK2 JAK2/STAT3 JAK2/STAT3 signaling janus lung Lung injury lung tissue molecular analysis molecular mechanism Necrosis phosphorylated pulmonary fibrosis pulmonary inflammation reduced representing SARS-CoV-2 serum Signaling staining STAT3 TGF-β1 therapeutic therapeutic effect TNFα treat Treatment with COVID-19 worldwide pandemic [DOI] 10.18632/aging.203874 PMC 바로가기 [Article Type] Research Paper
The Efficacy and Safety of Janus Kinase Inhibitors for Patients With COVID-19: A Living Systematic Review and Meta-AnalysisMedicine Published on 2022-01-272022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] 95% CI adverse events adverse outcomes Analysis Baricitinib baseline Clinical outcome contribute COVID-19 database decrease decreased mortality demonstrated Efficacy and safety eligible evaluated Evidence Hospitalized hospitalized patient incidence increased mortality JAK inhibitor jak inhibitors janus Janus kinase Janus kinase inhibitors kinase Meta-analysis Mortality no increase observational study outcome Patient patients with COVID-19 Randomized controlled trial RCTs Registration required Result retrieved review risk ruxolitinib Safety SARS-CoV-2 searched significant decrease significantly subgroup analysis supplemental oxygen systematic review the cytokine storm Tofacitinib Treatment Ventilation with COVID-19 [DOI] 10.3389/fmed.2021.800492 PMC 바로가기 [Article Type] Medicine
Genetic Predisposition and Inflammatory Inhibitors in COVID-19: Where Do We Stand?Review Published on 2022-01-242022-10-28 Journal: Biomedicines [Category] COVID-19, [키워드] “cytokine storm” ACE2 Activation acute respiratory distress acute respiratory syndrome administration alteration angiotensin-converting enzyme-2 anti-inflammatory agent Arrhythmias cardiovascular complication Clinical course Clinical outcome Colchicine concerning Coronavirus disease-19 Corticosteroids COVID-19 Cytokines detrimental endothelial epithelial cells events fatality genetics global pandemic histocompatibility complex Inflammation interferon gamma janus myocarditis non-specific Patient patients with COVID-19 Prognosis Respiratory system resulting SARS-CoV-2 signaling pathway subsequent syndrome therapeutic Toll-like receptor Transcription tumor necrosis factor-alpha Vascular viral entry widespread [DOI] 10.3390/biomedicines10020242 PMC 바로가기 [Article Type] Review
Janus Kinase Signaling Pathway and Its Role in COVID-19 Inflammatory, Vascular, and Thrombotic ManifestationsReview Published on 2022-01-172022-10-31 Journal: Cells [Category] COVID-19, [키워드] activated addition catastrophic Coagulation system Coagulopathy concerning contribute COVID-19 COVID-19 patients Cytokine storm disease dysregulation endothelial cells Infection Inflammation Jak JAK inhibitor janus Janus kinase Janus kinase signaling kinase manifestation mechanism Mortality organ dysfunction Organ failure organs patients Perturbation phenotype Platelets presenting public health crisis role SARS-CoV-2 SARS-COV-2 infection Signaling the disease therapeutic these cell thrombosis thrombotic triggering [DOI] 10.3390/cells11020306 PMC 바로가기 [Article Type] Review
Exploring potential mechanisms of Suhexiang Pill against COVID-19 based on network pharmacology and molecular docking네트워크 약리학 및 분자 도킹을 기반으로 Covid-19에 대한 수 헥치 안약의 잠재적 메커니즘 탐색4200 Published on 2021-12-232022-08-31 Journal: Medicine [Category] 유전자 메커니즘, 치료제, [키워드] activator Analysis Anti-viral applied AutoDock binding affinity biological processe cells chemokine Chinese classic collected Compound compounds coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 disease Cytokine storm Cytoscape software database Diagnosis disease endothelial epidermal epidermal growth factor Functional enrichment analysis GeneCard Genes growth factor guideline hub genes hypoxia immune function immune system include inflammatory storm ingredient interleukin interleukin 17 interleukin 6 Intersection janus Janus kinase KEGG Kyoto mechanism moderate molecular docking molecular mechanism Necrosis network pharmacology Ontology pathway enrichment Pathways phosphatidylinositol phosphatidylinositol 3-kinase PI3K pill plague platform potential mechanism potential therapeutic targets predicted Protein kinase B protein-protein interaction R language receptor Regulation screened severe COVID-19 signaling pathways STAT3 suggested suhexiang pill synergistic T cell T cell receptor target target gene Target genes targets TNF Traditional Chinese medicine Transcription Treatment Tumor tumor necrosis tumor necrosis factor Vascular Viral viral invasion was used [DOI] 10.1097/MD.0000000000027112 PMC 바로가기 [Article Type] 4200
JAK-STAT Pathway: A Novel Target to Tackle Viral InfectionsReview Published on 2021-11-272022-10-28 Journal: Viruses [Category] COVID-19, [키워드] Antiviral antiviral target candidate cellular comparable COVID-19 disorder Efficacy Inflammation innate immune response Innate immunity interfere JAK inhibitor Jak-STAT JAK-STAT signaling janus knowledge Local novel pathway Regulation representing safety profile systemic inflammation target Therapeutic strategies therapeutic target Transcription Treatment viral infection viral infections virus [DOI] 10.3390/v13122379 PMC 바로가기 [Article Type] Review
The JAK/STAT signaling pathway: from bench to clinicReview Article Published on 2021-11-262022-10-04 Journal: Signal Transduction and Targeted Therapy [Category] 바이오마커, 변종, 치료제, [키워드] Activation Autoimmune diseases Cancer cellular processes Critical Diseases dysregulation Evidence expression highlight Immunopathogenesis induce Inflammation inhibitor JAK/STAT JAK/STAT pathway JAK/STAT signaling janus knowledge Molecular biology Molecular medicine Regulation Signaling signaling pathway Transcription [DOI] 10.1038/s41392-021-00791-1 PMC 바로가기 [Article Type] Review Article
Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials야누스 키나제 억제제와 코로나19 주요 결과: 야누스의 두 얼굴을 잊어야 할 때! 무작위 대조 시험의 메타 분석Meta-Analysis Published on 2021-11-012022-09-11 Journal: Clinical Rheumatology [Category] SARS, 임상, [키워드] added Adult patients antibody production assigned Baricitinib benefit concerning coronavirus disease coronavirus disease-2019 COVID-19 COVID-19 infection Cytokine storm database death disease ECMO Efficacy Endpoint ENhance evaluate extracorporeal membrane oxygenation global public health In-hospital Inflammatory response inhibitor Jak JAK inhibitor jak inhibitors janus Janus kinase Janus kinase inhibitor Kinase inhibitor Mechanical mechanical ventilation mechanism Meta-analysis Mortality nezulcitinib nightmare outcome outcomes pathophysiologic Patient patients with COVID-19 Randomized controlled trial Randomized controlled trials RCT RCTs reduction in risk risk reduction ruxolitinib searched significant decrease stages Standard of care subject Tofacitinib Treatment [DOI] 10.1007/s10067-021-05884-4 PMC 바로가기 [Article Type] Meta-Analysis
Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trialsCOVID-19에 대한 Janus kinase inhibitors의 임상적 효능 및 안전성: 무작위 대조 시험의 체계적인 검토 및 메타 분석Meta-Analysis Published on 2021-10-012022-09-11 Journal: International immunopharmacology [Category] SARS, 신약개발, 임상, [키워드] 95% CI adverse event all-cause mortality rate And tofacitinib Baricitinib clinical Clinical efficacy Clinical outcome clinical recovery ClinicalTrials Control Controlled controlled trials controls COVID-19 COVID-19 patients Efficacy and safety hospitalized COVID-19 patients inception inhibitor Invasive mechanical ventilation Jak JAK inhibitor jak inhibitors janus Janus kinase Janus kinase inhibitor Kinase inhibitor Meta-analysis mortality rate no significant difference Placebo Primary outcome Randomized controlled trial Randomized controlled trials RCT RCTs receiving risk ruxolitinib Safe searched Serious Adverse Event Serious Adverse Events standard care systematic review the patient Time to recovery Tofacitinib treating COVID-19 patient Treatment [DOI] 10.1016/j.intimp.2021.108027 PMC 바로가기 [Article Type] Meta-Analysis
ORF3a Protein of Severe Acute Respiratory Syndrome Coronavirus 2 Inhibits Interferon-Activated Janus Kinase/Signal Transducer and Activator of Transcription Signaling via Elevating Suppressor of Cytokine Signaling 1Microbiology Published on 2021-09-282022-10-31 Journal: Frontiers in Microbiology [Category] COVID-19, [키워드] accelerated accessory protein ORF3a activator acute respiratory syndrome Analysis appear blocked caused contribute coronavirus coronavirus 2 Coronavirus disease 2019 COVID-19 cytokine signaling dampen Degradation domain dose Elevating evade global public health host antiviral response host immune responses IFN IFN signaling inhibited interferon JAK/STAT signaling JAK2 janus Janus kinase Janus kinase 2 (JAK2) mechanism ORF3a outbreak pathogen Phosphorylation promoted Protein respiratory responsible SARS-CoV-2 SARS-CoV-2 viral Signaling siRNA SOCS1 STAT Stat1 suppressed suppressor Transcription transducer ubiquitin-proteasomal degradation upregulating upregulation [DOI] 10.3389/fmicb.2021.752597 PMC 바로가기 [Article Type] Microbiology